Literature DB >> 20107148

Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome.

Dirk Haller1, Jean-Michel Antoine, Stig Bengmark, Paul Enck, Ger T Rijkers, Irene Lenoir-Wijnkoop.   

Abstract

Ulcerative colitis and Crohn's disease, the 2 distinct idiopathic pathologies of inflammatory bowel diseases, are spontaneously relapsing, immunologically mediated disorders of the gastrointestinal tract. Selected probiotics strains have been proven to be clinically effective in maintaining remission in patients with ulcerative colitis. None of the probiotics thus far tested has been shown to be effective in induction of remission or in maintenance of remission in patients with Crohn's disease. The multispecies probiotics mixture of 8 strains seems effective in the maintenance of remission in pouchitis. Irritable bowel syndrome is a functional bowel disorder manifested by chronic, recurring abdominal pain or discomfort associated with disturbed bowel habit in the absence of structural abnormalities likely to account for these symptoms. Recently conducted appropriately powered studies with different (combinations of) probiotics show positive results on reduction of symptoms, although a considerable placebo effect is also found. Mechanistic studies aimed at pathophysiological mechanisms of inflammatory bowel diseases can identify new targets for probiotic bacteria.

Entities:  

Mesh:

Year:  2010        PMID: 20107148     DOI: 10.3945/jn.109.113746

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  26 in total

1.  Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics.

Authors:  Theo S Plantinga; Wendy W C van Maren; Jeroen van Bergenhenegouwen; Marjolijn Hameetman; Stefan Nierkens; Cor Jacobs; Dirk J de Jong; Leo A B Joosten; Belinda van't Land; Johan Garssen; Gosse J Adema; Mihai G Netea
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

Review 2.  Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease.

Authors:  Collin L Ellis; John C Rutledge; Mark A Underwood
Journal:  Gut Microbes       Date:  2010 Nov-Dec

Review 3.  Health benefits of probiotics: are mixtures more effective than single strains?

Authors:  C M C Chapman; G R Gibson; I Rowland
Journal:  Eur J Nutr       Date:  2011-01-13       Impact factor: 5.614

Review 4.  Actual concept of "probiotics": is it more functional to science or business?

Authors:  Michele Caselli; Francesca Cassol; Girolamo Calò; John Holton; Giovanni Zuliani; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

5.  Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial.

Authors:  Ji Yeon Kim; Yeo Jin Park; Hyo Jin Lee; Min Young Park; Oran Kwon
Journal:  Food Sci Biotechnol       Date:  2017-12-12       Impact factor: 2.391

6.  VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis.

Authors:  Cong Dai; Chang-Qing Zheng; Fan-Ji Meng; Zheng Zhou; Li-Xuan Sang; Min Jiang
Journal:  Mol Cell Biochem       Date:  2012-10-23       Impact factor: 3.396

7.  Predominant effect of host genetics on levels of Lactobacillus johnsonii bacteria in the mouse gut.

Authors:  Keren Buhnik-Rosenblau; Yael Danin-Poleg; Yechezkel Kashi
Journal:  Appl Environ Microbiol       Date:  2011-07-29       Impact factor: 4.792

8.  Lactobacillus plantarum surface layer adhesive protein protects intestinal epithelial cells against tight junction injury induced by enteropathogenic Escherichia coli.

Authors:  Zhihua Liu; Tongyi Shen; Peng Zhang; Yanlei Ma; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

9.  Test-based exclusion diets in gastro-esophageal reflux disease patients: a randomized controlled pilot trial.

Authors:  Michele Caselli; Giovanni Zuliani; Francesca Cassol; Nadia Fusetti; Elena Zeni; Natalina Lo Cascio; Cecilia Soavi; Sergio Gullini
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Probiotics can alleviate cardiopulmonary bypass-induced intestinal mucosa damage in rats.

Authors:  Ying-Jie Sun; Hui-Juan Cao; Dan-Dan Song; Yu-Gang Diao; Jin Zhou; Tie-Zheng Zhang
Journal:  Dig Dis Sci       Date:  2013-01-19       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.